BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11435967)

  • 1. Economic analysis of basiliximab in renal transplantation.
    Keown PA; Balshaw R; Krueger H; Baladi JF
    Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost evaluation of basiliximab treatment for renal transplant patients in Japan.
    Hasegawa T; Imai H; Miki S
    Pharmacoeconomics; 2003; 21(11):791-806. PubMed ID: 12859220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
    Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A
    BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation.
    Lorber MI; Fastenau J; Wilson D; DiCesare J; Hall ML
    Clin Transplant; 2000 Oct; 14(5):479-85. PubMed ID: 11048993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
    Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.
    Keown PA; Kiberd B; Balshaw R; Khorasheh S; Marra C; Belitsky P; Kalo Z
    Pharmacoeconomics; 2004; 22(10):621-32. PubMed ID: 15244488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
    Walters SJ; Whitfield M; Akehurst RL; Chilcott JB
    Pharmacoeconomics; 2003; 21(2):129-38. PubMed ID: 12515574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
    Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD; Rajagopalan PR; Hall M
    Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.
    Filipponi F; Callea F; Salizzoni M; Grazi GL; Fassati LR; Rossi M; Risaliti A; Burra P; Agnes S; De Carlis L; Valente U; Ferrara R; Pisati R
    Transplantation; 2004 Nov; 78(10):1488-95. PubMed ID: 15599313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
    Parrott NR; Hammad AQ; Watson CJ; Lodge JP; Andrews CD
    Transplantation; 2005 Feb; 79(3):344-8. PubMed ID: 15699766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
    Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
    Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.